Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706413 | 0.98 | HPGD (0.49) | USP2SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL8210703 | 0.87 | KMT2A (0.55) | SMN1; SMN2MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL2862442 | 0.82 | ALDH1A1 (0.60) | SMN1; SMN2MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL20058376 | 0.82 | CYP2D6 (0.48) | USP2SMN1; SMN2MEN1KMT2AGPR119 | |
| SCHEMBL18785460 | 0.81 | MGLL (0.58) | USP2TSHRALDH1A1OPRD1OPRK1 | |
| SCHEMBL18608789 | 0.81 | MEN1 (0.58) | SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL13925211 | 0.81 | CD4 (0.47) | MEN1KMT2AGPR119TSHRALDH1A1 | |
| SCHEMBL18084793 | 0.80 | SMN1; SMN2 (0.80) | USP2SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL20274773 | 0.78 | TP53 (0.50) | MEN1KMT2AGPR119TSHRSTS | |
| SCHEMBL3863834 | 0.78 | KMT2A (0.63) | SMN1; SMN2MEN1KMT2AHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | SGK1, SGK2, SIK1 | USP2 2031/4885SMN1; SMN2 2955/4885MEN1 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.